PMEF
SPRY icon

Point72 Middle East FZE’s ARS Pharmaceuticals SPRY Stock Holding History

Point72 Middle East FZE’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,011
Closed -$32.6K – 2030
2023
Q1 		$32.6K Buy
+5,011
New +$38.5K ﹤0.01% 1350

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Middle East FZE's SPRY Position: Q2 2023 in Review

Point72 Middle East FZE sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 5,011 shares — an estimated $32.6K sold.

Point72 Middle East FZE first reported a position in SPRY in Q1 2023 and held it in 1 quarter. The position peaked at $32.6K in Q1 2023. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

  • Point72 Middle East FZE reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,011 ARS Pharmaceuticals shares in Q2 2023, an estimated $32.6K.
  • Point72 Middle East FZE first reported a position in ARS Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's ARS Pharmaceuticals position peaked at $32.6K in Q1 2023.
  • 92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.